Treatment of high‑grade osteoblastic osteosarcoma of the humerus in a 5‑year‑old boy with cystic fibrosis: A case report

Okuda,Kenichi   V.; Hammermann,Jutta; Lange,Björn   S.; Fischer,Jana   C.; Thielemann,Falk; Knöfler,Ralf; Suttorp,Meinolf

doi:10.3892/mco.2017.1274

Treatment of high‑grade osteoblastic osteosarcoma of the humerus in a 5‑year‑old boy with cystic fibrosis: A case report

Authors:
- Kenichi V. Okuda
- Jutta Hammermann
- Björn S. Lange
- Jana C. Fischer
- Falk Thielemann
- Ralf Knöfler
- Meinolf Suttorp
View Affiliations

Affiliations: Department of Pediatrics, University Hospital ‘Carl Gustav Carus’, Technical University, D‑01307 Dresden, Germany, Department of Orthopedics and Traumatology, University Hospital ‘Carl Gustav Carus’, Technical University, D‑01307 Dresden, Germany
Published online on: May 29, 2017 https://doi.org/10.3892/mco.2017.1274
Pages: 148-150

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Antineoplastic treatment of osteoblastic osteosarcoma in a patient with cystic fibrosis (CF) may harbor a high risk of neutropenia‑associated complications, and, to the best of our knowledge, has not been previously reported. Diagnosis of CF was confirmed in a 6‑week‑old boy following pathological newborn screening. The patient had a stable course of CF under standardized continuous therapy. At the age of 5 years, osteosarcoma of the left proximal humerus was diagnosed without evidence of metastases. Neoadjuvant chemotherapy, including doxorubicin, cisplatin and methotrexate, was administered for 10 weeks. The patient tolerated this therapy relatively well, with a continuous antibiotic prophylaxis of cefuroxime without experiencing major complications; in particular, no pulmonary exacerbations were observed as a consequence of immunosuppression or mucosal toxicity. The tumor responded well, and amputation of the limb was avoided via the use of ‘clavicle per humerus’ osteosynthesis. Postoperatively, compartmental syndrome occurred, requiring management by fasciotomy. Adjuvant chemotherapy was applied thereafter again, without major toxicity that would have required dose reduction. Under intensive physiotherapy, the mobility of the left arm and hand was deemed to be satisfactory. The coincidence of CF with osteosarcoma is extremely rare, and, to the best of our knowledge, has not been previously described. Under antibiotic prophylaxis, antineoplastic treatment was possible without major complications during neutropenia.

View Figures

View References

1	Welsh MJ and Smith AE: Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell. 73:1251–1254. 1993. View Article : Google Scholar : PubMed/NCBI
2	Dodge JA: A millennial view of cystic fibrosis. Dev Period Med. 19:9–13. 2015.PubMed/NCBI
3	Mirabello L, Troisi RJ and Savage SA: Osteosarcoma incidence and survival rates from 1973 to 2004: Data from the surveillance, epidemiology, and end results program. Cancer. 115:1531–1543. 2009. View Article : Google Scholar : PubMed/NCBI
4	Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, Kotz R, Salzer-Kuntschik M, Werner M, Winkelmann W, et al: Prognostic factors in high-grade osteosarcoma of the extremities or trunk: An analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 20:776–790. 2002. View Article : Google Scholar : PubMed/NCBI
5	Mueller EL, Walkovich KJ, Mody R, Gebremariam A and Davis MM: Hospital discharges for fever and neutropenia in pediatric cancer patients: United States, 2009. BMC Cancer. 15:3882015. View Article : Google Scholar : PubMed/NCBI
6	Trotti A, Byhardt R, Stetz J, Gwede C, Corn B, Fu K, Gunderson L, McCormick B, Morrisintegral M, Rich T, et al: Common toxicity criteria: Version 2.0. an improved reference for grading the acute effects of cancer treatment: Impact on radiotherapy. Int J Radiat Oncol Biol Phys. 47:13–47. 2000. View Article : Google Scholar : PubMed/NCBI
7	Mavrogenis AF, Abati CN, Romagnoli C and Ruggieri P: Similar survival but better function for patients after limb salvage versus amputation for distal tibia osteosarcoma. Clin Orthop. 470:1735–1748. 2012. View Article : Google Scholar : PubMed/NCBI
8	Whelan JS, Bielack SS, Marina N, Smeland S, Jovic G, Hook JM, Krailo M, Anninga J, Butterfass-Bahloul T, Böhling T, et al: EURAMOS-1, an international randomised study for osteosarcoma: Results from pre-randomisation treatment. Ann Oncol. 26:407–414. 2015. View Article : Google Scholar : PubMed/NCBI
9	Bielack SS, Smeland S, Whelan JS, Marina N, Jovic G, Hook JM, Krailo MD, Gebhardt M, Pápai Z, Meyer J, et al: Methotrexate, doxorubicin and cisplatin (MAP) plus maintenance pegylated interferon alfa-2b versus MAP alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: First results of the EURAMOS-1 good response randomized controlled trial. J Clin Oncol. 33:2279–2287. 2015. View Article : Google Scholar : PubMed/NCBI
10	Winkelmann WW: Clavicula pro humero-a new surgical method for malignant tumors of the proximal humerus. Z Orthop Ihre Grenzgeb. 130:197–201. 1992. View Article : Google Scholar : PubMed/NCBI
11	Salzer-Kuntschik M, Delling G, Beron G and Sigmund R: Morphological grades of regression in osteosarcoma after polychemotherapy - study COSS 80. J Cancer Res Clin Oncol. 106 Suppl:S21–S24. 1983. View Article : Google Scholar
12	Scotet V, Duguépéroux I, Saliou P, Rault G, Roussey M, Audrézet MP and Férec C: Evidence for decline in the incidence of cystic fibrosis: A 35-year observational study in Brittany, France. Orphanet J Rare Dis. 7:142012. View Article : Google Scholar : PubMed/NCBI
13	Demeyer S, De Boeck K, Witters P and Cosaert K: Beyond pancreatic insufficiency and liver disease in cystic fibrosis. Eur J Pediatr. 175:881–894. 2016. View Article : Google Scholar : PubMed/NCBI
14	Fink AK, Yanik EL, Marshall BC, Wilschanski M, Lynch CF, Austin AA, Copeland G, Safaeian M and Engels EA: Cancer risk among lung transplant recipients with cystic fibrosis. J Cyst Fibros. 16:91–97. 2017. View Article : Google Scholar : PubMed/NCBI
15	Maisonneuve P, Marshall BC and Lowenfels AB: Risk of pancreatic cancer in patients with cystic fibrosis. Gut. 56:1327–1328. 2007. View Article : Google Scholar : PubMed/NCBI
16	Neglia JP, Wielinski CL and Warwick WJ: Cancer risk among patients with cystic fibrosis. J Pediatr. 119:764–766. 1991. View Article : Google Scholar : PubMed/NCBI
17	Yen EH, Quinton H and Borowitz D: Better nutritional status in early childhood is associated with improved clinical outcomes and survival in patients with cystic fibrosis. J Pediatr. 162:530–535.e1. 2013. View Article : Google Scholar : PubMed/NCBI
18	Steinkamp G and von der Hardt H: Improvement of nutritional status and lung function after long-term nocturnal gastrostomy feedings in cystic fibrosis. J Pediatr. 124:244–249. 1994. View Article : Google Scholar : PubMed/NCBI